Results from recent clinical trials of targeted agents in patients with relapsed DLBCL not eligible for stem cell transplant
NORR (%)95% CICR (%)Median DOR (mo)Median PFS (mo)Median OS (mo)
Brentuximab lenalidomide1  37 57 39.6-72.5 35 13.1 10.2 14.3 
Rituximab lenalidomide ibrutinib6  39 44 28-60 28 15.9 5.5 9.5 
Tafasitamab lenalidomide5  80 57.5 45.9-68.5 40 43.9 11.6 33.5 
Polatuzumab bendamustine rituximab7  106 41.5 NR 38.7 9.5 6.6 12.5 
Loncastuximab8  145 48.3 39.9-56.7 24.1 10.3 4.9 9.9 
NORR (%)95% CICR (%)Median DOR (mo)Median PFS (mo)Median OS (mo)
Brentuximab lenalidomide1  37 57 39.6-72.5 35 13.1 10.2 14.3 
Rituximab lenalidomide ibrutinib6  39 44 28-60 28 15.9 5.5 9.5 
Tafasitamab lenalidomide5  80 57.5 45.9-68.5 40 43.9 11.6 33.5 
Polatuzumab bendamustine rituximab7  106 41.5 NR 38.7 9.5 6.6 12.5 
Loncastuximab8  145 48.3 39.9-56.7 24.1 10.3 4.9 9.9 

CR, complete response; DOR, duration of response; NR, nonresponder; OS, overall survival; PFS, progression-free survival.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal